Clinical Trials Search Results

A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigators Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma

NAUTIKA1: A MULTICENTER, PHASE II, NEOADJUVANT AND ADJUVANT STUDY OF MULTIPLE THERAPIES IN BIOMARKER-SELECTED PATIENTS WITH RESECTABLE STAGES IB-III NON-SMALL CELL LUNG CANCER

Phase III Randomized Trial of Immunotherapy with or without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma

A Phase 2 study of Canakinumab in patients with Myelofibrosis

A Phase II Randomized Study of Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer with PSA Progression while on NHA and LHRH Analog

Neoadjuvant Therapy of HER2 directed Dendritic Cell (DC1) vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients with HER-2 Positive Breast Cancer (NATASHA trial)

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies

A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)

Phase II Study of Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]

A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer

A Platform Study of RAS(ON) Inhibitors to Treat Patients with Gastrointestinal Solid tumor - SUB-A: Study of RMC-6236 in Combination with 5-flourouracil-based regimens in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma, - SUB: Study of RMC-6236 in Combination with Cetuximab with or without mFOLFOX6 in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma, - SUB-C: Study of RMC-6236 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma - SUB-D: Study of RMC-9805 with or without RMC-6236 in Combination with 5-flourouracil-based Therapies in Patients with RAS G12D-Mutant Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma - SUB-E: Study of RMC-9805 with or without RMC-6236 in Combination with Cetuximab-based Therapies in Patients with RAS G12D-Mutant Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma - SUB-F: Study of RMC-9805 With or Without RMC-6236 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with RAS G12D-Mutant Metastatic Pancreatic Ductal Adenocarcinoma

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenace Therapy in Adult Patients with Newly Diagnosed FLT3-ITD (-) Acute Myeloid Leukemia